Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia

Background and Objectives The molecular analysis of minimal residual disease (MRD) may provide informaton on the risk of recurrence in patients with acute lymphoblastic leukemia (ALL). The aim of this study was to correlate the kinetics of MRD clearance after allogeneic transplantation with the clin...

Full description

Bibliographic Details
Published in:	Haematologica
Main Authors:	Orietta Spinelli, Barbara Peruta, Manuela Tosi, Vittoria Guerini, Anna Salvi, Maria Cristina Zanotti, Elena Oldani, Anna Grassi, Tamara Intermesoli, Caterina Micò, Giuseppe Rossi, Pietro Fabris, Giorgio Lambertenghi-Deliliers, Emanuele Angelucci, Tiziano Barbui, Renato Bassan, Alessandro Rambaldi
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2007-05-01
Online Access:	https://haematologica.org/article/view/4432

Similar Items

Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival
by: Silvia Salmoiraghi, et al.
Published: (2016-06-01)

Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status
by: Guido Finazzi, et al.
Published: (2007-01-01)

PROGNOSTIC SIGNIFICANCE AND TREATMENT IMPLICATIONS OF MINIMAL RESIDUAL DISEASE STUDIES IN PHILADELPHIA-NEGATIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA
by: Orietta Spinelli, et al.
Published: (2014-08-01)

Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study
by: Martino Introna, et al.
Published: (2007-07-01)

P063 | DIGITAL DROPLET PCR FOR MINIMAL RESIDUAL DISEASE MONITORING IN PHILADELPHIA NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA: A REPORT FROM THE PROSPECTIVE NORTHERN ITALY LEUKEMIA GROUP (NILG) ALL 10/07 STUDY
by: F. Ballardini, et al.
Published: (2025-09-01)

CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease
by: Francesco Mannelli, et al.
Published: (2012-04-01)

P1180: BURKITT INTERNATIONAL PROGNOSTIC INDEX EVALUATED IN PATIENTS TREATED WITH R-GMALL PROTOCOL
by: Giuliana Rizzuto, et al.
Published: (2023-08-01)

Concurrent diagnosis of acute myeloid leukemia and symptomatic COVID-19 infection: a case report successfully treated with Azacitidine-Venetoclax combination
by: Daniela Taurino, et al.
Published: (2021-08-01)

Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia
by: Renato Bassan, et al.
Published: (2015-06-01)

Lymphoproliferative disease and acquired C1 inhibitor deficiency
by: Roberto Castelli, et al.
Published: (2007-05-01)

High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program
by: Tamara Intermesoli, et al.
Published: (2013-11-01)

Allogeneic stem cell transplantation for thalassemia major
by: Emanuele Angelucci, et al.
Published: (2008-12-01)

ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
by: Federico Lussana, et al.
Published: (2014-10-01)

An agenda for future research projects in polycythemia vera and essential thrombocythemia
by: Tiziano Barbui, et al.
Published: (2020-08-01)

No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials
by: Tiziano Barbui, et al.
Published: (2017-06-01)

Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma
by: Luca Agnelli, et al.
Published: (2007-01-01)

Appropriate management of Polycythemia Vera with cytoreductive drug therapy
by: Tiziano BARBUI
Published: (2022-10-01)

Clonal hematopoiesis and inflammation: a link with thrombosis and malignancy
by: Tiziano Barbui
Published: (2022-07-01)

Genetically modified and unmodified cellular approaches to enhance graft versus leukemia effect, without increasing graft versus host disease: the use of allogeneic cytokine-induced killer cells
by: Benedetta Rambaldi, et al.
Published: (2024-10-01)

Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial
by: Gianluca Cavallaro, et al.
Published: (2024-08-01)

Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06
by: Chiara Caprioli, et al.
Published: (2020-08-01)

C4d Deposition after Allogeneic Renal Transplantation in Rats Is Involved in Initial Apoptotic Cell Clearance
by: Stefan Reuter, et al.
Published: (2021-12-01)

Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors
by: Tiziano Barbui, et al.
Published: (2024-10-01)

Prediction models for essential thrombocythemia from two longitudinal studies involving 2000 patients
by: Tiziano Barbui, et al.
Published: (2024-01-01)

Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study
by: Arianna Ghirardi, et al.
Published: (2024-04-01)

A novel, highly sensitive and rapid allele-specific loop-mediated amplification assay for the detection of the JAK2V617F mutation in chronic myeloproliferative neoplasms
by: Giulia Minnucci, et al.
Published: (2012-09-01)

Frequent occurrence of non-malignant genetic alterations in clinical grade mesenchymal stromal cells expanded for cell therapy protocols
by: Chiara Capelli, et al.
Published: (2014-06-01)

Optimizing investigator-led oncology research in Europe
by: Tiziano Barbui, et al.
Published: (2012-06-01)

Cancer survivorship programs: time for concerted action
by: Tiziano Barbui, et al.
Published: (2014-08-01)

Leukocytosis and thrombosis in polycythemia vera: can clinical trials settle the debate?
by: Tiziano Barbui, et al.
Published: (2019-12-01)

Immunosuppression and Rejection of Cartilage Formed by Allogeneic Chondrocytes in Rats
by: Anna Osiecka-Iwan, et al.
Published: (1999-11-01)

Allogeneic transplantation in lymphoma: current status
by: Norbert Schmitz, et al.
Published: (2007-11-01)

The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients
by: Tiziano Barbui, et al.
Published: (2023-12-01)

Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant
by: Federica Sora, et al.
Published: (2022-07-01)

Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment
by: Tiziano Barbui, et al.
Published: (2022-01-01)

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
by: Federico Lussana, et al.
Published: (2017-02-01)

Editorial: The Red Cell Life-Cycle From Erythropoiesis to Clearance
by: Lars Kaestner, et al.
Published: (2018-11-01)

Advanced Fuel Property Data Platform: Overview and Potential Applications
by: Simon Blakey, et al.
Published: (2022-03-01)

Binding Analogy. A Polemical Geography of Women’s Abolitionism
by: Anna Guerini
Published: (2024-02-01)

Donor Lymphocyte Infusions After Allogeneic Stem Cell Transplantation in Acute Leukemia: A Survey From the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
by: Francesca Patriarca, et al.
Published: (2020-10-01)